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Abstract
Magnetic resonance imaging (MRI) is one of the most important medical imag-
ing methods due to its noninvasiveness, superior versatility and resolution. In
order to improve the image quality and to make diﬀerent tissues more distin-
guishable, MRI is often used together with contrast agents. Contrast agents
are most commonly based on gadolinium. However, during recent decades, the
group of metal-free contrast agents has become a major area of development.
One striking group of potential metal-free contrast agents are the nitroxides,
stable organic radicals.
In this thesis, two fully organic, metal-free nitroxides were designed and syn-
thesized. The compounds consisted of a nitroxide moiety bearing the contrast
enhancing properties and a targeting moiety aimed to invoke speciﬁcity of the
agent towards tumor tissue. Their stability and relaxation enhancing prop-
erties were determined in order to evaluate their potential as novel contrast
agents for MRI. Both of the compounds proved to be highly stable by maintain-
ing their contrast and relaxation enhancing properties for several hours is harsh
conditions. Also, they displayed eﬀective relaxation time shortening in MRI
experiments. Therefore, these organic radical contrast agents are expected to
bring a noteworthy addition to the established MRI-based diagnostics by join-
ing the growing group of metal-free contrast agents for MRI.
Another medical diagnostic method based on magnetic resonance is magnetic
resonance spectroscopy (MRS) and spectroscopic imaging (MRSI). In the lat-
ter section of the thesis a novel organic marker for MRS and MRSI with no
existing equivalent was developed. Although the phantom MRS studies seemed
promising, unfortunately the in vivo animal studies did not give the desired
outcome leaving place for improvement.
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1 Introduction
1.1 Magnetic resonance imaging
Nuclear magnetic resonance (NMR) phenomenon has become an important
tool for chemists, physicist as well as medical professionals. The ﬁrst experi-
ments to detect and measure the magnetic properties of atoms and molecules
are dating back the 1940s.1–3 Since those times, NMR spectroscopy has be-
come commonplace as a structural characterization method in many research
laboratories. In the 1970s, the NMR phenomenon was reﬁned to study sub-
jects in vivo by introducing gradients to the magnetic ﬁeld.4–7 The method
featured localization of the signals to produce images with spatial information
and to create anatomical images. The method was called magnetic resonance
imaging (MRI), and the ﬁrst scanners appeared in clinical use in the 1980s.
MRI is a versatile imaging method that can be used in neuro-, cardiovas-
cular and musculoskeletal imaging as well as in angiography. The imaging
is based on creating contrast between diﬀerent tissue types or malignant and
healthy tissue. The contrast can be further improved with optimization of
imaging parameters and pulse sequences, or utilizing contrast agents. This the-
sis will focus on contrast enhancement with contrast agents. Constant progress
for developing more eﬃcient scanners, superior resolution and non-invasiveness
have made MRI one of the most important diagnostic media. Also, currently
the moderate expenses have made MRI instruments readily available in ma-
jority of hospitals.
1.1.1 Basic principle of MRI
The main diﬀerence between MRI and for example X-ray or computer tomog-
raphy (CT) is the utilization of magnetic ﬁelds and radio frequency (RF) pulses
rather than ionizing radiation. Also, it does not apply radioactive tracers like
positron emission tomography (PET). MRI typically measures the magnetic
properties of the hydrogen nuclei of water molecules, the most abundant species
in living organisms. Hydrogen nuclei, or protons, are spinning charged particles
with a spin quantum number (I) of 1/2, that produces a local magnetic ﬁeld
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called magnetic moment. Upon application of an external magnetic ﬁeld, the
spins start to precess at Larmor frequency (ω0) (Figure 1.1). The Larmor fre-
quency is proportional to the strength of the magnetic ﬁeld and gyromagnetic
ratio (γ) that is speciﬁc for each nucleus. For hydrogen, the gyromagnetic ratio
is 42.58 MHz/T meaning that the magnetic moment μ of 1H nuclei precesses
at 42.58 MHz frequency in a 1.0 T magnetic ﬁeld.
Figure 1.1 Precession of a nuclear spin in an external magnetic ﬁeld.8
The application of the external magnetic ﬁeld B0, also generates a net
magnetization (M) along the ﬁeld as the majority of the spins align themselves
parallel to the magnetic ﬁeld. The phenomenon is commonly described by a
vector model, where B0 and M are considered to be placed along the z-axis.
Measuring the small net magnetization parallel to an extremely powerful B0
is virtually impossible. Therefore, the alignment of the net magnetization is
manipulated by an RF pulse oscillating at Larmor frequency. A pulse given at
the Larmor frequency utilizes resonance eﬀect and is powerful enough to distort
the net magnetization away from the strong B0. This generates a magnetic
ﬁeld B1 on the transverse plane.
Upon the application of the RF pulse, the net magnetization begins to
precess about the B1 and the M rotates away from the z-axis (Figure 1.2a).
Due to the simultaneous precession about the z-axis, the rotation occurs as
a spiral motion. Therefore, in order to simplify the vector model, it is com-
monly presented in a rotating frame where B1 is set parallel to x’-axis. As in
Figure 1.2a, a 90◦ RF pulse ﬂips the magnetization into the transverse plane
(Figure 1.2b). After the RF pulse is switched oﬀ, the precession occurs solely
along the z-axis. The receiver coil set on the transverse plane detects this as
an oscillating magnetic ﬁeld. Simultaneously, the net magnetization starts to
return to the thermal equilibrium state by realigning itself along the z-axis.
Also, the individual spins precessing together begin to dephase and lose co-
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herence. As a result of these processes, longitudinal and transverse relaxation,
respectively, the detected signal starts to decay over time, which is collected
by the detector as a free induction decay (FID) (Figure 1.2c).
Figure 1.2 A simple vector model on the eﬀect of RF radiation. (a) The
net magnetization M begins to precess about the magnetic ﬁeld
B1. (b) After a 90◦ RF pulse, the net magnetization M is in the
transverse plane. The ﬂipped magnetization starts to precess
along the z-axis. (c) The signal is collected at the receiver coil
as a free induction decay (FID).
1.1.2 Relaxation
The image contrast is built on various factors. These include proton density,
diﬀerent imaging parameters and most importantly the relaxation of protons.
The foundations for the NMR relaxation theory were laid in the 1940s by
Bloembergen Purcell and Pound.9 The relaxation phenomenon is a complex
process involving various factors making its detailed description laborious.10–12
Furthermore, in living tissue, a large variety of molecular environments further
complicates the process.8 In brief, relaxation in MRI is mainly based on dipole-
dipole interactions. These interactions take place between nuclei that are in
constant motion, which generates ﬂuctuating magnetic ﬁelds with a broad fre-
quency band.13 The dipole-dipole interactions between nuclei and unpaired
electrons are remarkably stronger than between nuclei due to the large mag-
netic moment of the electron. Contrast agents as relaxation enhancing sub-
stances are based on this eﬀect, and they will be discussed in more detail in
section 1.1.3.
As described in the previous section, there are two types of relaxations
following the RF pulse; longitudinal and transverse relaxation. Transverse re-
laxation (T2), or spin-spin relaxation, is the process where excited spins lose
their phase coherence.14 This is due to small inconsistencies in the magnetic
ﬁeld contributed by each spin locally, which changes the precession frequen-
cies of the neighboring spins. As the spins adapt their precession frequency
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to the ﬂuctuating magnetic ﬁeld, they eventually become totally out of phase
in regard to each other. Longitudinal relaxation (T1) is where the net mag-
netization realigns itself along the z-axis as spins give up the energy obtained
from the RF pulse to the surrounding lattice. Therefore, it is also known as
spin-lattice relaxation.
As relaxation is closely linked to the motion of the nuclei, it is convenient to
introduce a time constant called rotational correlation time (τR). It describes
roughly the time between two successive reorientations of the molecule.13 Tak-
ing account the resonance eﬀect, the most eﬀective T1 relaxation is obtained
when ω0τR ≈ 1.15 Thus, the T1 of medium-sized molecules is short, while small
molecules with short rotational correlation times have long T1, as well as large
molecules with long τR. In turn, T2 relaxation is most eﬀective, when τR is
long. Therefore, the T2 shortens as the molecular size increases.
The water molecules in living tissue can roughly be divided into three
groups: bound-, structured- and free water.14 Free water, for example cere-
brospinal ﬂuid (CSF), moves around rapidly and has small τR. Due to its
constant change in motion, tumbling occurs over a wide range of frequencies.
Therefore, only small amount of ﬂuctuations take place at Larmor frequency
resulting in long T1 (Figure 1.3). Also, the fast ﬂuctuation causes rapid changes
in the local magnetic ﬁeld and the ﬁeld relative to proton seems homogenous.
This phenomenon, often referred to as motional averaging, causes slow dephas-
ing and long T2. Correspondingly, water bound to large macromolecules has
long τR leading to long T1 but short T2. Most of the water in tissues is so
called structured water that is somewhere between the free and bound water.
It tumbles at a frequency quite near the Larmor frequency generating short T1
and medium T2.
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Figure 1.3 The eﬀect of rotational correlation time τR on relaxation times
T1 and T2. Adapted from Bloembergen et al.9
In MRI, the contrast corresponds to diﬀerences in signal intensities de-
scribing divergent tissues, that make the image more distinguishable. The
contrast can be controlled by varying the imaging methods and using diﬀerent
weightings. For instance, choosing the sequence parameters so that the con-
trast reﬂects mainly the variations in T1 corresponds to T1-weighting. Echo
time and repetition time are critical parameters in creating diﬀerent weight-
ings. Echo time (TE) is the time from the center of the RF pulse to the center
of the echo (the peak of the time domain signal) whereas repetition time (TR)
is the time between successive RF pulses.
As the recovery of the magnetization along the z-axis is due to the longi-
tudinal relaxation T1, it can be emphasized by optimizing the TR. Increasing
TR long enough eventually enables complete T1 relaxation. This creates high
signal intensities for all tissue types, but simultaneously the contrast between
tissue types decreases as the signal intensities become closer to each other. If
TR is short, the longitudinal magnetization will be partially saturated leading
to lower signal intensity. The degree of saturation and thus the signal intensity
depend on tissue T1 leading to contrast between tissues with diﬀerent T1 val-
ues. During TE, the transverse magnetization decreases due to T2 relaxation.
Thus, as TE increases, the signal intensity decreases. However, the eﬀect of
TE on the intensities and contrast depends on the T2 value of the tissue under
study. With these facts in mind, for T1-weighting TE and TR should be short
for maximized T1- and minimized T2 contrast. Similarly, T2-weighting is ob-
tained by selecting long TE and TR. Tissues with short T2 appear as darkened
areas in T2 weighted images whereas tissues with short T2 will appear bright in
T1-weighted images. Minimizing both T2 and T2 contrasts by selecting short
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TE and long TR, creates a proton density (PD) image. In PD scans, the
brightness of the image is determined by the number of protons in the area of
interest.
1.1.3 Contrast agents
In general, substantial part of MRI development focuses on imaging techniques
but also the signiﬁcance of contrast agents has grown over time. There are
countless ways to categorize contrast agents but probably the most favored
one is to highlight two main groups, T1 and T2 contrast agents. The majority
of contrast agents are based on paramagnetic metals. They possess unpaired
electrons that induce a positive magnetic susceptibility and can alter the sur-
rounding magnetic ﬁeld.16 Due to the local changes in the magnetic ﬁeld and
the dipolar interactions between protons and unpaired electrons, paramagnetic
agents act as relaxation enhancers. This causes shortening in the relaxation
times of the protons in the near vicinity. The relaxation enhancing eﬃciency
is often described with the term relaxivity. Relaxivities r1 and r2 are measures
of a change in the relaxation rates R1 and R2 (1/T1 and 1/T2, respectively)
normalized to the contrast agent concentration. Usually, they are deﬁned by
the slopes of R1 and R2 as a function of concentration.
In addition to the contrast agent concentration, other important factors in
relaxation enhancement are related to the structures of the contrast agents.17
Hydration number (q) indicates the amount of water molecules that can coor-
dinate to the contrast agent molecule at a time. The larger the number, the
better the eﬃciency of the contrast agent is. In addition, the distance between
the water molecule and the paramagnetic center correlates with the relaxation
eﬃciency. The relaxation is most eﬀective when the distance is short. Of the
dynamic factors, rotational correlation time (τR), and water residence lifetime
(τM ) are the most relevant ones. As presented earlier, rotational correlation
time describes the movement of the molecule. Contrast agents with long τR
have generally better relaxivity. The residence lifetime of the bound water is
the time water molecules stay in contact with the contrast agent molecule. The
residence time should be long enough for the water molecules to become fully
relaxed, but short enough to optimize the water exchange rate, leading to the
most eﬃcient relaxation.18
1.1.3.1 T1 contrast agents
T1 contrast agents are known to shorten escpecially the T1 time of the nearby
nuclei. This is observed as a brightening of the image in T1-weighted MRI. The
clear majority of clinically used contrast agents is based on the paramagnetic
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metal gadolinium (Gd3+).19–21 Also, the ﬁrst contrast agent approved for clin-
ical use was gadolinium-based. This agent was Gd(DTPA) (gadopentetate
dimeglumine) (1, Scheme 1.1) also known as Magnevist by Schering AG.22–27
The popularity of gadolinium-based contrast agents (GBCAs) can be cred-
ited mainly to three unique characteristics of gadolinium; the large number of
unpaired electrons, high magnetic moment and long electron spin relaxation.
Gadolinium has seven unpaired electrons inducing a powerful magnetic mo-
ment. The symmetry of the electronic state of gadolinium elongates the elec-
tron spin relaxation outclassing some other lanthanides with stronger magnetic
moments.
In human body, free gadolinium is higly toxic. As the ionic radius of Gd3+
is close to Ca2+, it can bind to Ca2+ ion channels and replace calcium in Ca2+
binding enzymes and proteins.21,28 In order to reduce the toxicity, the metal
ions are bound to ligands. However, in some cases the chelation may have a
negative eﬀect on the relaxation enhancing properties. The contrast agents
are required to be thermodynamically stable and kinetically inert. Usually,
the kinetic properties are more substantial than thermodynamic properties as
the time the agents spend in human body before excretion through kidneys is
small (biological half-life 1.5 h). Table 1.1 lists the six most common GBCAs,
including their generic and trade names, as well as their r1 values measured in
1.5 T and 3.0 T ﬁelds.29 The molecular structures are given in Scheme 1.1.
Table 1.1 Common Gd-based MRI-contrast agents.
Chemical name Generic name Trade name r1*
1.5 T 3 T
Gd(DTPA) (1) Gadopentetatedimeglumine Magnevist 4.1 3.7
Gd(DTPA-BMA) (2) Gadodiamide Omniscan 4.3 4.0
Gd(DTPA-BMEA) (3) Gadoversetamide OptiMARK 4.7 4.5
Gd(BOPTA) (4) Gadobenic acid MultiHance 6.3 5.5
Gd(DOTA) (5) Gadoteric acid Dotarem 3.6 3.5
Gd(DO3A-butrol) (6) Gadobutrol Gadovist 5.2 5.0
*in plasma at 37 ◦C (mM-1 s-1)
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Scheme 1.1 Structures of common Gd-based MRI-contrast agents.
Compounds (1–4) have linear structures whereas (5–6) are macrocycles.
It has been noted that cyclic GBCAs are more inert than the linear agents.
The ionic charge aﬀects the stability, ionic agents (1, 4, and 5) being more
stable than the non-ionic ones. The possible mechanisms for the Gd3+ re-
lease from the contrast agents are transmetallation, transchelation and metal
dissociation.20 Gadolinium-based contrast agents were considered fully safe
until 2006, when it was ﬁrst reported, that they may cause a condition called
nephrogenic systemic ﬁbrosis (NSF).30 Patients with renal disorders should not
be subjected to GBCA injections during imaging. The disease causes ﬁbrosis
of sceletal muscle and visceral organs with no eﬀective treatment.31–33
A study by Kanda et al.34 revealed Gd accumulating in brain even for
patients with no renal dysfuction. Typically the deposition is observed with
patients subjected to repeated GBCA administrations.35–37 For the these rea-
sons, FDA (Food and Drug Administration) gave new recommendations to
avoid repeated use of GBCAs38 and EMA (European Medicines Agency) a re-
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ferral to suspend or restrict use of the four linear GBCAs (1–4, Scheme 1.1).39
Furthermore, anthropogenic gadolinium has been found in aquatic environ-
ment migrated through waste-water.40,41 Traces of gadolinium have even been
found from drinking water.42 For these reasons, the research community has
initiated to seek new groups of contrast agents.
In addition to gadolinium-based contrast agents, there are examples of T1
contrast agents based on manganese.43,44 However, they have not progressed
to clinical use.
1.1.3.2 T2 contrast agents
All MRI contrast agents shorten both T1 and T2 relaxation times. However,
while gadolinium increases somewhat similar amounts of R1 and R2, in tis-
sue the relative change in R1 is much larger than in R2.19 The r1 often
also experiences slight decrease in stronger magnetic ﬁelds, whereas r2 is not
aﬀected. T2 contrast agents are mainly superparamagnetic iron nanoparti-
cles due to their anisotropic susceptibility eﬀects. The use of nanoparticles
enables functionalization for selective targeting, multimodality, and therapy
applications. The oxide is often coated with dextran, carboxydextran or sili-
cates. Currently, there are superparamagnetic iron oxide 50-500 nm (SPIO),
ultrasmall superparamagnetic 4-50 nm (USPIO), monocrystalline (MION) and
cross-linked (CLIO) contrast agents.45 These are speciﬁcally used in liver imag-
ing.46 However, due to severe allergic reactions caused by many SPIO agents,
their development has been stopped and some have even been withdrawn from
the market.47
1.1.3.3 Metal-free contrast agents
As an alternative to metal-based contrast agents, some metal-free contrast en-
hancement methods for MRI have been developed. Probably the two most im-
portant ones are chemical exchange saturation transfer (CEST) and hyperpo-
larized (HP) techniques. The ﬁrst method, CEST is a technique which probes
saturation of exchangeable protons in the target molecules.48 Exchangeable
protons can be found for example in agents containing amine (-NH2) and car-
boxylic (-COOH) groups. The contrast in CEST is based on the decrease in the
bulk water signal intensity, caused by selective saturation of the exchangeable
protons.49
CEST agents can be roughly divided into paramagnetic and metal-free dia-
magnetic agents.49,50 Diamagnetic CEST agents (DIACEST) include sugars,
amino acids, nucleosides, indoles, pyrimidines and polymers with exchange-
able protons. While these are exogenous agents, endogenous CEST (endo-
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CEST) takes advantage on the endogenous molecules with exchangeable pro-
tons. These include for example some metabolites, proteins and peptides. The
advantages of CEST are the possibility to detect several agents at the same
time, and to study the micro-environment through their physico-chemical and
biological parameters.
The other group of metal-free agents, hyperpolarized agents, are used
mainly in studying metabolic pathways in cancer, cardiac diseases, and lung
functions.51 The method is based on hyperpolarizing the imaging agent before
rapid administration to the subject.52 The created hyperpolarized state, where
the population of the spins in the lower and higher energy states is altered so,
that the population in the lower energy state is considerably larger, signiﬁ-
cantly increases the sensitivity. Using this technique, also nonproton nuclei
can be imaged.
Hyperpolarized agents are often divided into gases (3He and 129Xe) and
liquid state (13C and 15N) agents. HP gases are used mainly for lung imag-
ing.53 Heteronuclei 13C and 15N are used as labels for diﬀerent metabolites.54
Examples of these metabolites comprise pyruvate, fumarate, dehydroascorbic
acid—ascorbic acid (DHA—AA), bicarbonate, urea and glutamine. There are
several hyperpolarization techniques: spin-exchange optical pumping (SEOP)
and metastability exchange (ME) for gases, and dynamic nuclear polarization
(DNP), parahydrogen-induced polarization (PHIP) and signal ampliﬁcation by
reversible exchange (SABRE) for liquids.
The downside of aforementioned methods is the need for special hardware.
For example, using hyperpolarized agents, an external polarizing device is re-
quired. Another emerging group of metal-free contrast agents, nitroxyl radi-
cals, can be readily applied for imaging with the existing routine techniques.
Like metals, nitroxyl radicals are paramagnetic species and could provide a
valuable addition to the metal-free imaging agents.
1.2 Nitroxyl radicals
Typically, radicals are considered as a highly reactive species. However, there
are also stable and persistent radicals. Persistent radicals are often regarded as
a species that can be observed with spectroscopic methods but are not stable
enough to be isolated or handled in ambient conditions. Stable radicals, on
the other hand, can be isolated, stored and used in chemical reactions with-
out tethering the radical center. The most common groups of stable organic
radicals include phenyl- hydrazyl- and nitroxyl radicals. Nitroxyl radicals, or
nitroxides are probably the largest and most studied group of stable radicals.
They are N,N -disubstituted N—O radicals with one unpaired electron delocal-
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ized between the nitrogen and oxygen atoms. Nitroxides have a great variety of
applications in organic synthesis,55–59 polymerization,60 and as spin labels,61
molecular magnets,62,63 and organic batteries.64–68
1.2.1 Nitroxides as metal-free contrast agents for MRI
Nitroxides were ﬁrst studied as potential contrast agents for MRI already in
the 1980s, simultaneously with the ﬁrst GBCAs.69–73 However, the nitroxides
used at that time were not stable enough and seemed to reduce to diamagnetic
hydroxylamines quite rapidly. Also, the relaxation eﬀect given by GBCAs
was much higher and they became the principal contrast agents. Since the
development of MRI scanners and pulse sequences, and the search for metal-
free contrast agents, the research of nitroxide-based contrast agents emerged
in the 1990s, peaking its popularity in recent years. To overcome the issues
of instability towards natural reductants and defective relaxivities, structural
modiﬁcations have been the main thread in the research. The popularity of
nitroxides as organic contrast agents can be accredited to the high stability
and compact size of the molecules compared to other stable organic radicals,
such as phenyl and hydrazyl radicals. Nitroxides act mainly as T1 contrast
enhancing agents, except for few examples.
1.2.1.1 Stability
Based on rapid bioreduction, nitroxides were initially considered suboptimal
contrast agents for MRI.74 Since then, extensive studies concerning nitroxide
stability have been conducted and some consistencies in the structure-reactivity
relationship have been found. Depending on the substituents in the α-position,
instead of delocalizing between the nitrogen and the oxygen atoms, the un-
paired electron can further delocalize in the whole structure, which destabilizes
the radical. Also, hydrogens in the α-position markedly decrease the stability
causing a disproportionation reaction between two nitroxide molecules to form
a hydroxylamine and a nitrone. The mechanism has been proposed to fol-
low a direct hydrogen atom abstraction75 (pathway a in Scheme 1.2) or single
electron transfer via head-to-tail-dimer through ion pair to proton transfer76
(pathway b, Scheme 1.2) depending on the nitroxide structure.77 There are
also stable α-hydrogen nitroxides as presented in Scheme 1.3. These bridged
bicyclic nitroxides are unable to form nitrones based on Brendt’s rule.78
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Scheme 1.2 Disproportionation mechanism for nitroxide with α-hydrogen.
The reaction via direct hydrogen atom abstraction (a) and sin-
gle electron transfer via head-to-tail-dimer through ion pair to
proton transfer (b).
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Scheme 1.3 Examples of stable nitroxides with α-hydrogen.
Nitroxides can undergo either oxidation or reduction reactions, both of
which produce a diamagnetic, non-contrast enhancing equivalents of the rad-
ical form. The redox cycle of nitroxide radicals in Scheme 1.4 shows the one-
electron oxidation and reduction of the radical 15, to oxoammonium 16 and
hydroxylamine 17, respectively. In living organisms, reduction is the pre-
dominant process where the ascorbic acid and certain enzymes act as natural
reductants. Oxidation process takes place mainly in the event of oxidative
stress.79
1.2. NITROXYL RADICALS 13
N
O
OR
N
O
OR
N
OH
OR
+e- +e-
-e--e-
Predominant reaction in the
living organisms at pH 7.4
16 15 17
Scheme 1.4 Redox cycle of nitroxide radicals.80
In spite of the poor stability of the ﬁrst nitroxide contrast agents, they
seemed to have high potential and improving their stability became a common
research objective.81 The stability can be substantially improved by optimizing
the structure. The structure–reactivity relationship is often assessed by mea-
suring the redox potentials by cyclic voltammetry82 or detecting the EPR (elec-
tron paramagnetic resonance) signal decay rate during the reaction between
nitroxide and ascorbic acid.83 These studies are often supported with com-
putational methods, for instance geometry optimization84 and SOMO–LUMO
(singly occupied molecular orbital–lowest unoccupied molecular orbital) en-
ergy calculations.85 The greatest single factor behind nitroxide stability is
the size of its side groups in the α-position of the N—O moiety. The stabil-
ity of the radical is proportional to the steric shielding provided by the side
groups. According to reaction kinetic measurements, the shielding increases
from gem-methyl to spirocyclohexyl to gem-ethyl (Scheme 1.5).84
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Scheme 1.5 The eﬀect of the ring size and the side groups to the stability
of diﬀerent nitroxides.
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According to the experimental data gem–diethyl groups provide more ef-
fective steric shielding to the nitroxide moiety than the spirocyclohexyl groups.
Indeed, this can be conﬁrmed for example with space-ﬁlling plots of the X-ray
structures.84 Furthermore, adding heteroatoms in the spiro rings reduces the
stability as they can act as electron-withdrawing groups. This reduces the
electron density around the nitroxide moiety, which favors the reduction.85
Also, the ring size has an eﬀect on the stability, 5-membered pyrrolidine being
more stable than the 6-membered piperidine. The ring size seems to aﬀect the
accessibility of the reductant to the radical center.86
While optimizing the structure of a nitroxide-based contrast agent, there
is a ﬁne balance between stability and relaxivity. Some bulky side groups
may increase the distance between the radical center and the water molecule
so, that the eﬃciency of the relaxation enhancement decreases. On the other
hand, the side groups should be large enough to prevent rapid bioreduction.
1.2.1.2 Functional modiﬁcations
By modifying the structures of the nitroxides, it is possible to create func-
tional and more stable nitroxide contrast agents. For example, to image
joints87 and to detect proteoglycans in knee cartilage,88 an ionic nitroxide
(24, Scheme 1.6) was developed and used eﬀectively. A contrast agent with
improved water-solubility and stability towards reduction was constructed by
adding NO-moiety to imidazol-4-yl 2-imidazoline (25).89,90 Even more stable
4-oxo-TEEPO (4-oxo-2,2,6,6-tetraethylpiperidin-1-oxyl, 26) radical was used
for brain MR imaging as it proved to be able to cross healthy blood–brain
barrier (BBB).91
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Scheme 1.6 The structures of some nitroxide-based contrast agents.
Generally, small sized nitroxides can penetrate the BBB. This feature is im-
portant while imaging early-stage brain tumors with still intact BBB.92 Also,
these compounds oﬀer a convenient method to study the BBB permeability
of drugs, for instance. A study on the BBB permeability of a cancer drug
lomustine (27, Scheme 1.7) was conducted by labeling the drug with a nitrox-
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ide.93,94 The distribution of the resulting compound SLENU (28) in mouse
brain was detected with MRI as an improved T1 relaxivity. The same agent was
used to image cancer by detecting carcinogenesis with diﬀerent redox activities
between normal and cancer tissue.80,95
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Scheme 1.7 The anticancer drug lomustine and corresponding MRI contrast
enhancing nitroxide SLENU.
To construct small molecule tissue targeting agents, nitroxides have been
attached to ibuprofen (29, Scheme 1.8) and ketoprofen (30).96 These theranos-
tic compounds were used for both therapeutic and diagnostic purposes acting
as anti-inﬂammatory drugs and dual MRI/EPRI contrast agents, respectively.
Mitochondria targeted mito-TEMPO (31) was used to study superoxide pro-
duction in the dopaminergic area of the brain in Parkinson’s disease97 and
mitochondrial dysfunction.98
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Scheme 1.8 The structures of ibuprofen and ketoprofen nitroxides, and
mito-TEMPO.
A common technique to increase the relaxivity of nitroxide-based contrast
agents is to reduce their tumbling and increase the rotational correlation time
τR. The most obvious way to do so, is to enlarge the molecular size. Nitroxides
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have been widely attached to natural and synthetic macromolecules that can
act as an excellent backbone for diﬀerent surface functionalities. They can also
carry several nitroxide units to further increase the relaxivity. These macro-
molecules include for instance DNA oligomers,99–101 viruses,102 nanotubes,103
self-asseblying polyradicals104–107 and lyotropic liquid crystal nanoparticles.108
There are also targeting macromolecular nitroxides possessing dual optical/MR
imaging capabilities, like polyacetylene derivatives carrying folic acid and ni-
troxides,109 and glucose functionalized ﬂuorecent carbon quantum dots.110
Hyperbranched macromolecules, DAB (polypropylene imine)111,112 and PA-
MAM (polyamidoamine)113,114 dendrimers have also been linked to nitroxides.
However, these compounds have relatively low relaxivities and poor water-
solubility. The water-solubility can be increased by adding polyethylene glycol
(PEG) groups to the structure. These PEG groups also immobilize nitroxides
and improve the access of water molecules to the paramagnetic centers, causing
more eﬀective relaxation enhancement.115
Macrocyclic calix[4]arenes provide more rigid radical scaﬀold which im-
proves τR. With suitable linkers, they provide positions for up to eight radical
moieties producing for example tetra- and octaradicals (Scheme 1.9). In addi-
tion, the interactions between the unpaired electrons within the calix[4]arene
structures improve the T1 relaxation eﬀect.116 These interactions are through-
bond and through-space exchange couplings and they occur in both 1,3-alternate
(32) and cone (33) conformations (Scheme 1.9).117 However, all couplings ex-
cept through-bond exchange in cone are antiferromagnetic, thus 1,3-alternate
conformation is preferred.118 Other eﬀective examples of rigid polymers carry-
ing nitroxides include N -(2-Hydroxypropyl) methacrylamide (HPMA) copoly-
mers,119 polyacetylenes,109 brush-arm star polymers (BASP),120–122 heparin,123
polyurethanes,124 and hyperbranched polystyrene.125
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Scheme 1.9 Tetraradical and octaradical calix[4]arene nitroxides.
1.2.2 Electron paramagnetic resonance imaging of nitroxides
In addition to MRI, nitroxides can be used as electron paramagnetic resonance
imaging (EPRI) probes. Electron paramagnetic resonance (EPR) is based
on the same phenomenon as NMR, only instead of protons, the behaviour
of electrons is monitored. Both protons and electrons are spinning charged
particles, apart for the fact that electrons are in constant motion, inducing
much larger dipole moment. As opposed to NMR, in EPR spectroscopy the
frequency is kept constant, while the magnetic ﬁeld is varied.
Nitroxides are commonly used as spin labels to study the structures and
dynamics of macromolecules such as proteins with EPR spectroscopy.126 Also,
imidazolium based nitroxides can be used as pH-indicators due to their pH-
sensitive protonation mechanism, which is observed as a change in the EPR
spectrum.127,128 It is also possible to image living organisms with EPR al-
though it is still resticted to animals. EPR imaging is mostly used to study
redox metabolism and hypoxia.129–131 Also, the pharmacokinetics, such as
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spreading and metabolism of spin labeled drugs, can be studied with EPRI.132
1.3 Magnetic resonance spectroscopy
In addition to producing anatomical images, biological tissues and their chemi-
cal compositions can be examined with NMR spectra in vivo. In vivo NMR, or
better known as magnetic resonance spectroscopy (MRS), is used to study dis-
eases based on changes in metabolites especially in the brain area.133,134 These
diseases include for instance brain tumors, epilepsy and stroke. Other possible
targets for MRS are muscle, liver and prostate.135,136 The most common nu-
cleus measured with MRS is proton, 1H, due to its high natural abundance and
sensitivity.137 Whereas in MRI the properties of water protons are detected,
MRS is focused on the protons of metabolites, which are 10,000 times less
concentrated.138 Also, phosphorus 31P, carbon 13C, ﬂuorine 19F and sodium
23Na spectroscopy are used in some extent. However, while in 1H spectroscopy,
standard RF coils and software can be used, non-proton spectroscopy requires
special coils as well as other instrumentation such as preampliﬁers matching
them.
1.3.1 Metabolites
With 1H MRS, a large number of biologically important metabolites can be de-
tected and analyzed. The most common brain metabolites studied with MRS
are lactate (Lac, 36), N -acetyl aspartate (NAA, 37), glutamate–glutamine
(Glu–Gln, 38), total creatine (tCr) comprising creatine (39) and phosphocre-
atine, choline containing compounds i.e. choline (Cho, 40), phosphopcholine
and glyserophosphocholine, and myo-inositol (mI, 41) (Scheme 1.10). Each
metabolite has its own function in living organisms (Table 1.2).
The absolute quantiﬁcation of MR spectra is performed using a concen-
tration reference.139 The water signal can be used as an internal reference
while an external reference is created with a phantom. Absolute quantiﬁcation
also requires the use of some signal correction factors like relaxation times. In
clinical use, deﬁning the relative concentrations is often suﬃcient. It is per-
formed by comparing the intensities of the metabolite signals. The most com-
mon ratios under inspection in studies of neurological diseases are NAA/Cho,
NAA/creatine and Cho/creatine. NAA often decreases in brain tumors and
inﬂammatory processes whereas choline increases as it indicates myelin break-
down or rapid cell proliferation. Creatine is often used as a reference compound
as its intensity hardly changes in most cases excluding brain tumors. To study
hypoxia, lactate is often used as a reference due to its presence in anaerobic
processes.
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Scheme 1.10 Structures of the most common metabolites in brain detected
with 1H MR-spectroscopy. Red color indicates the molecular
regions consisting of the protons responsible for characteristic
signals listed in Table 1.2.
Table 1.2 Most common metabolites in brain 1H spectroscopy.
Metabolite ppm c (mM) Multiplicity Function
Lac (36) 1.33 0.2-1 doublet Anaerobic metabolite
NAA (37) 2.02 7.5-17 singlet Neuron and axon marker
Glu-Gln (38) 2.05-2.50 6-12.5 (Glu)3-6 (Gln) multiplet Neurotransmitters
creatine (39) 3.02 4.5-10.5 singlet Energy metabolism
Cho (40) 3.22 0.5-2.5 singlet Membrane marker
mI (41) 3.56 4-9 singlet Glial marker
1.3.2 Techniques
Since metabolites appear at signiﬁcantly lower intensities compared to water,
water suppression techniques are essential in MRS. Water suppression is used to
reduce the water signal appearing at 4.8 ppm and to obtain informative spectra.
Also, in some cases fat suppression is needed to reduce the lipid resonances at
1.3 ppm. Probably the most common water suppression technique is CHEmical
Shift-Selective (CHESS) sequence.140 In the technique, frequency selective
excitation pulses are used to rotate the water proton magnetization repeatedly
into the transverse plane. Then, the magnetization is purged by application
of pulsed ﬁeld gradients. There are several variants of CHESS such as WET
(Water suppression Enhanced Through T1)141 and VAPOR (VAriable Power
pulses with Optimized Relaxation delays).142
There are two main options for spatial location in in vivo NMR: single voxel
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spectroscopy (SVS) and chemical shift imaging (CSI), also referred as magnetic
resonance spectroscopic imaging (MRSI). With SVS, a spectrum of a single vol-
ume element, voxel, is recorded from one speciﬁc location, whereas with CSI,
a larger selected volume of interest (VOI) is monitored consisting of simulta-
neous excitation of many smaller voxels. While SVS is a more quantitative
method, CSI produces metabolite maps oﬀering information on distribution of
various metabolites within the VOI. The most common sequences used with
MRS are PRESS (Point Resolved Spectroscopy)143 and STEAM (Stimulated
Echo Acquisition Mode).144 They both utilize three slice selective pulses to
produce a spin echo or stimulated echo. In STEAM, three 90◦ pulses are used
and in PRESS one 90◦ pulse is followed by two 180◦ pulses.
The advantage of PRESS is the high SNR (signal-to-noise) ratio, which is
two times higher than the SNR obtained with STEAM. On the other hand,
STEAM enables the use of very short TE. TE is often chosen according to
the metabolites of interest, since using long TE only displays NAA, Cho, Cr
and Lac signals while macromolecules and lipids decay to the noise level. Both
sequences are commonly used, albeit PRESS is somewhat more common in
clinical use.
2 Aims of the research
Noninvasive imaging is of vital importance in modern medical diagnostics.
Magnetic resonance imaging (MRI) is a powerful tool especially when com-
bined with contrast agents. Compared to the other common imaging methods,
planar X-ray, CT and PET, the advantages of MRI are the lack of ionizing
radiation, good soft tissue contrast and the broad accessibility of MRI imaging
facilities. Due to the non-speciﬁcity and health-related issues associated with
the widespread use of gadolinium-based contrast agents, a metal-free, tumor-
targeting contrast agent would bring a substantial addition to the established
MRI-based diagnostics. Therefore, the aims of the main part of the research
were to develop stable nitroxide-based contrast agents with tumor targeting
properties.
The second, smaller part of the research consisted of developing a tumor tar-
geting marker compound for 1H magnetic resonance spectroscopy and spectro-
scopic imaging (MRS and MRSI), methods applicable with MRI facilities. To
the date, there are no targeting markers for MRS or MRSI.
Speciﬁcally, the aims of the research were:
1. to design and synthesize stable nitroxides conjugated with suitable tar-
geting units to act as organic, metal-free contrast agents for MRI;
2. to assess their relaxation enhancing abilities with magnetic resonance
studies in vitro and in vivo;
3. to design and synthesize an organic marker with potential tumor target-
ing moiety for MRS and MRSI;
4. to conduct in vitro and in vivo MRS and MRSI studies to assess the ap-
plicability of the compound as a tumor targeting marker for MRS/MRSI.
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3 Methods
In general, the detailed analytical and experimental methods on synthesis and
application studies of the radical contrast agents are described in publications
I–III. The unpublished experimental methods for the study of the organic
marker for MRS and MRSI are presented herein. Furthermore, the author
participated in designing the study, performed the synthesis of the marker
compound and its stability study, prepared the phantom and analyzed the
results.
3.1 General methods
The blood plasma was purchased from the Finnish Red Cross Blood Service.
The chemicals were acquired from commercial sources and used without further
puriﬁcation. The NMR spectra were recorded with a Varian Unity Inova 500
NMR-spectrometer (500 MHz 1H-frequency, 11.7 T). The high-resolution mass
spectroscopy (MS) was conducted with a Bruker Micro TOF with electron
spray ionization (ESI).
3.2 Synthesis of TMSEt-Glc
2-(Trimethylsilyl)ethyl β-D-glucopyranoside (57): To a solution of 2-
(Trimethylsilyl)ethyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside (56, 112 mg)
in 1 ml of methanol was added 1 ml of 25 % NH3 solution. The reaction
mixture was stirred at room temperature for two hours. The excess solvent
and NH3 were removed in vacuo and the crude product was separated by silica
gel column chromatography using 10% MeOH / DCM as eluent yielding 2-
(Trimethylsilyl)ethyl β-D-glucopyranoside 57 (70 mg, 99 %) as a white solid.
1H NMR (500 MHz, D2O): δ (ppm): 4.51 (d, 3J=7.9 Hz, 1 H, H -1’), 4.05-4.11
(ddd, 3J=5.2 Hz, 3J=10.0 Hz, 2J=-12.6 Hz, 1 H, CH2), 3.94-3.97 (dd, 3J=2.1
Hz, 2J=-12.3 Hz, 1 H, H -6a’), 3.78-3.83 (ddd, 3J=5.5 Hz, 3J=10.1 Hz, 2J=-
12.4 Hz, 1 H, CH2), 3.75-3.78 (dd, 3J=5.6 Hz, 2J=-12.3 Hz, 1 H, H -6b’), 3.52
(t, 3J=9.0 Hz, 1 H, H -3’), 3.31-3.35 (ddd, 3J=9.3 Hz, 3J=5.6 Hz, 3J=2.1 Hz,
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1 H, H -5’), 3.43 (t, 3J=9.3 Hz, 1 H, H -4’), 3.29 (t, 3J=8.6 Hz, 1 H, H -2’),
1.09-1.15 (td, 3J=5.5 Hz, 2J=-12.9 Hz, 1 H, CH2), 0.99-1.05 (td, 3J=5.2 Hz,
2J=-12.9 Hz, 1 H, CH2), -0.08 (s, 9 H, CH3). 13C NMR (126 MHz, D2O):
δ (ppm): 104.32 (C-1’), 78.71 (C-3’), 78.67 (C-5’), 75.93 (C-2’), 72.41 (C-4’),
71.13 (CH2), 63.53 (C-6’), 20.36 (CH2), 0.30 (CH3); MS (ESI) C11H24O6Si:
calc: 303.1234 [M+Na]+, found: 303.1233 [M+Na]+.
3.3 In vitro stability study
For the in vitro stability study, a 10 mM sample of TMSEt-Glc in blood plasma
with 10 % of D2O was prepared. The sample was incubated at 37 ◦C. The
stability of TMSEt-Glc was monitored with Varian Unity Inova 500 NMR-
spectrometer. Heteronuclear Multiple Bond Correlation (HMBC)145 spectra
were recorded after 1, 2, 3 and 24 hours of incubation.
3.4 Phantom study with MRS and MRSI
The phantom for the MRS and MRI study was constructed of TMSEt-Glc
samples in buﬀered solution containing metabolites L-glutamine (9 mM), phos-
phocholine chloride calcium salt tetrahydrate (2 mM), myo-inositol (4 mM),
sodium L-lactate (2 mM), N -acetyl aspartate (10 mM) and creatine (6 mM).
The buﬀer solution (pH 7.2) contained K2HPO4 x 3 H2O (72 mM), KH2PO4
(28 mM), Na-formate (200 mM) and NaN3 (1 g/l). The phantom comprised
seven NMR sample tubes (5 mm outer diameter) with TMSEt-Glc concentra-
tions of 0 mM, 0.0625 mM, 0.125 mM, 0.25 mM, 0.5 mM, 1 mM, 2 mM.
The phantom was imaged with a vertical 9.4 T magnet. For the single
voxel spectra, Point Resolved Spectroscopy (PRESS)143 was used. Repetition
time (TR) was 2 s, echo time (TE) 15 ms and spectral width (SW) 5020 Hz.
For the water suppression VAPOR142 (VAriable Power pulses with Optimized
Relaxation delays) was used. The voxel size was 3x3x3 mm, the number of
sampling points 4096 and the number of averages 256. For the chemical shift
imaging (CSI) spin echo sequence was used with TR of 2 s and TE of 12 ms. A
4 mm slice was imaged with VAPOR water suppression, 4096 sampling points
and 4 averages. The ﬁeld of view (FOV) was 20x20 mm and the phase encoding
matrix size 20x20.
4 Results and discussion
4.1 Organic radical contrast agents for MRI
Most of the traditional contrast agents for MRI lack selectivity and speciﬁcity.
However, radiopharmaceutical chemistry has a long history with target-speciﬁc
radiotracers.146 In this study, this approach was used by connecting a re-
laxation enhancing nitroxide with tumor-targeting units producing potential
contrast agents for MRI with speciﬁcity towards tumor tissue.
4.1.1 TEEPO-Glc and TEEPO-Met (I, II)
In the research, two nitroxides with potential contrast enhancing and tumor
targeting properties were synthesized. The relaxation enhancing nitroxide moi-
ety, TEEPO (2,2,6,6-tetraethylpiperidin-1-oxyl), was chosen based on its su-
perior stability and relatively small size. The purpose of using a small rad-
ical moiety was to avert any attenuation of the possible targeting properties
or blood-brain barrier permeability after attaching it to the targeting moiety.
Additionally, while the bulky ethyl side groups provide eﬀective steric shielding
to the radical center, the distance between water molecule and paramagnetic
center is short enough for an eﬀective relaxation enhancement. For the tar-
geting units, glucose (Glc) and methionine (Met) were selected owing to their
increased uptake in tumors due to the proliferation of cancer cells.147,148 Also,
both have been succesfully applied as targeting radiotracers in PET.149,150
There are multiple published synthetic routes for 4-oxo-TEEPO, which
acted as the precursor for further syntheses.151–153 In this study, the approach
via a pyrimidine intermediate was found the most suitable one (Scheme 4.1).151
The multistep synthesis was initiated with a reaction of 2-ethylbutene (42)
with chlorosulphonyl isocyanate to produce a β-lactam (43). After Boc protec-
tion (tert-butyloxycarbonyl), 44 was treated with methylmagnesiumbromide
yielding a β-aminoketone (45) through Grignard reaction. The deprotection
was performed with triﬂuoroacetic acid following a reaction with ammonia to
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produce a pyrimidine (46). It was further treated with 3-pentenone and NH4Br
and the resulting piperidinone (47) was oxidized to produce the 4-oxo-TEEPO
nitroxide (26).
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Scheme 4.1 Synthesis of 4-oxo-TEEPO 26 with reagents and conditions.
The conjugation of TEEPO to glucose was performed through glycosylation
reaction using ﬂuorinated glucose as the donor and boron triﬂuoride diethyl
etherate as a Lewis acid (Scheme 4.2).154 As for the acceptor, 4-oxo-TEEPO
(26) was reduced to 4-hydroxy-TEEPO (22) with NaBH4.155 The ﬂuorinated
glucose compound (α-F-glucose) was prepared by treating β-D-glucose pen-
taacetate with HF pyridine.156 The deacetylation of the glycosylated nitroxide
(48) was performed with aqueous ammonia solution yielding the ﬁnal prod-
uct 2,2,6,6-tetraethylpiperidin-1-oxyl-4-yl-β-D-glucopyranoside (TEEPO-Glc,
49).
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Scheme 4.2 Synthesis of TEEPO-Glc 49 with reagents and conditions.
TEEPO-Met was produced by attaching TEEPO to methionine through
an amide bond. For the reaction, 4-oxo-TEEPO 26 was transformed via 4-
carbonitrile-TEEPO 50 into 4-carboxy-TEEPO 51 .157 In the coupling re-
action, dicyclohexylcarbodiimide (DCC) was used as the activating agent in
the presence of hydroxybenzotriazole (HOBt) hydrate and 4-methylmorpholine
(NMM).158 The reaction produced 4-[(L-methionine methyl ester)carbonyl]-
2,2,6,6-tetraethylpiperidin-1-oxyl (TEEPO-Met-OMe, 52) and the methyl es-
ter protecting group was removed with NaOH yielding the ﬁnal product TEEPO-
Met 53.
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Scheme 4.3 Synthesis of TEEPO-Met 53 with reagents and conditions.
Also, less sterically shielded versions of the nitroxides were prepared as a
reference for the stability studies. The TEEPO nitroxide moiety was replaced
by TEMPO (2,2,6,6-tetramethylpiperidin-1-oxyl). The syntheses of TEMPO-
Glc and TEMPO-Met followed the same procedure as for TEEPO-Glc and
TEEPO-Met, respectively.
4.1.2 Stability towards reduction (I, II)
One of the most apparent concerns with radicals is their stability. Even though
4-oxo-TEEPO has proven to be stable,84,85 the conjugation of nitroxide to a
targeting unit may alter the radical stability.159 To ensure the stability of
the TEEPO-Glc and TEEPO-Met, NMR and EPR studies were conducted.
The main threat to the nitroxide stability is its reduction to corresponding
hydroxylamine by natural reductants, enzymes or antioxidants in human body.
In this study, ascorbic acid was used in great excess (10 to 20-fold) to observe
the reduction of the nitroxides to the corresponding hydroxylamines as these
in vitro results correspond well to the lifetime of the radicals in vivo.160
The reduction of TEEPO-Glc was studied with NMR spectroscopy by mon-
itoring the change of the water proton T1 relaxation time. As the paramag-
netic nitroxide reduces to diamagnetic hydroxylamine, it loses the ability to
shorten the T1 time of the nearby water protons and the relaxation time in-
creases. As the reduction may be fast, a rapid relaxation measurement had
to be used. Here, a method called Driven Equilibrium Single Pulse Observa-
tion of T1 (DESPOT) was used.161 In the method, two ﬂip angles (θ1 and θ2)
usually close to 45◦ and 90◦, are used and the T1 times are calculated using
4.1. ORGANIC RADICAL CONTRAST AGENTS FOR MRI 29
these angle values, the repetition time (TR) and the signal integrals (I1 and
I2) obtained from the aquisitions corresponding θ1 and θ2 (4.1).
T1 =
−TR
ln( I1 sin θ2 cos θ1−I2 sin θ1 cos θ2I1 sin θ2−I2 sin θ1 )
(4.1)
In the study, radical samples of TEEPO-Glc and TEMPO-Glc were pre-
pared in D2O with 1.6 % of H2O and a 10-fold excess of ascorbic acid was
added to the sample. As a result of a set of rapid T1 measurements, TEEPO-
Glc showed superior stability towards reduction. The relaxation enhancing
properties of TEEPO-Glc remained eﬀective for hours, whereas the less steri-
cally protected nitroxide TEMPO-Glc was completely reduced after less than
10 minutes (Figure 4.1a).
The stability of TEEPO-Met was studied with EPR by detecting the the de-
crease in the signal intensity as the amount of paramagnetic nitroxide dropped.
The TEEPO-Met and TEMPO-Met radical samples were prepared in phos-
phate buﬀered solution (PBS) corresponding to the pH of blood (7.4). The
samples were treated with a 20-fold molar excess of ascorbic acid and the de-
cay of high-ﬁeld EPR peak height was monitored with respect to time. Again,
TEEPO-Met showed good resistance towards reduction. After three hours only
10 % of TEEPO-Met was consumed in reductive conditions whereas TEMPO-
Met was almost fully reduced in 10 minutes (Figure 4.1b).
Figure 4.1 Reduction proﬁles of synthesized nitroxides. (a) The increase of
water proton T1 time of TEEPO-Glc (black circle) and TEMPO-
Glc (red triangle) with respect to time measured with NMR
spectroscopy in 11.7 T (500 MHz in 1H frequency) ﬁeld. (b)
The decrease of EPR signal of TEEPO-Met (black circle) and
TEMPO-Glc (red triangle) with respect to time.
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The results conﬁrmed the high stability of TEEPO-Glc and TEEPO-Met
towards reduction especially compared to their TEMPO equivalents, which is
in accordance with earlier studies on the stability of the nitroxide moieties.84,85
The stability of nitroxides can be attributed mainly to the steric hindrance
provided by the substituents adjacent to the radical centre. In summary, steric
hindrance both prevents disproportionation of two nitroxides and block the
access of reactive species to the radical centre.
4.1.3 Relaxometric studies in pre-clinical ﬁeld (I, II)
The contrast eﬀect in MRI is based on diﬀerences in relaxation times of diﬀerent
tissues. Contrast agents are used to enhance these diﬀerences by shortening
the water proton T1 relaxation time. The preliminary relaxometric studies of
TEEPO-Glc and TEEPO-Met were performed with 1H NMR spectroscopy in
pre-clinical magnetic ﬁeld (11.7 T) at 37 ◦C. The human blood plasma water
relaxation times (T1) and relaxation rates (R1) were measured as a function
of TEEPO-Glc and TEEPO-Met concentration. Both nitroxides conciderably
shortened the T1 and correspondingly increased the R1 of water in human blood
plasma (Figure 4.2). The TEEPO-Met samples contained 10 % of DMSO to
improve the solubility, which may cause a stronger relaxation enhancement
in those samples. With TEEPO-Glc, the T1 relaxation time halved when the
nitroxide concentration reached 2.5 mM, and further dropped to one third in
5 mM concentration. For TEEPO-Met, the respective concentration values
were 2 and 4 mM. The R1 rates increased linearly with the concentration,
implying that the contrast agents show no aggregation in the concentration
range studied.115 The relaxivities (r1) were deﬁned by the slopes of the linear
ﬁts of R1 as a function of concentration. The r1 values were 0.12 mM-1 s-1 and
0.17 mM-1 s-1 for TEEPO-Glc and TEEPO-Met, respectively.
4.1. ORGANIC RADICAL CONTRAST AGENTS FOR MRI 31
Figure 4.2 The blood plasma water T1 relaxation times and R1 relaxation
rates measured in 11.7 T magnetic ﬁeld (500 MHz 1H frequency)
at 37 ◦C in the presence of TEEPO-Glc and TEEPO-Met. (a)
T1 relaxation times as a function of TEEPO-Glc (black circle)
and TEEPO-Met (red triangle) concentrations. (b) R1 (1/T1)
relaxation rates as a function of TEEPO-Glc (black circle) and
TEEPO-Met (red triangle) concentrations.
4.1.4 Phantom studies in clinical ﬁeld (I, II)
To study the relaxation enhancing eﬀect of the TEEPO-Glc and TEEPO-Met
in clinical MRI magnetic ﬁeld strength, phantoms consisting of several sam-
ple vials with varying nitroxide concentrations in human blood plasma were
constructed and imaged with a 1.5 T clinical scanner. For TEEPO-Glc, con-
centrations of 0.2, 0.5, 1, 2, 5, 10 and 16 mM were selected for the phantom
(Figure 4.3a). Also, as a reference, three samples of clinically used contrast
agent, gadopentetate dimeglumine (Gd(DTPA)), were included in 0.01, 0.1
and 1 mM concentrations. The Gd(DTPA) concentrations were chosen to be
signiﬁcantly smaller compared to TEEPO-Glc as the relaxation eﬀect is more
eﬀective with GBCAs mainly due to gadoliniums seven unpaired electrons in
contrast to the one unpaired electron in TEEPO-Glc. From the T1-weighted
spoiled gradient echo fast low angle shot (FLASH) image (Figure 4.3b), it can
be seen that the intensity diﬀerence between undoped and nitroxide-doped
samples becomes visually detectable at a 0.5 mM concentration. Similar con-
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centrations of nitroxides have been detected in vivo in previously studies.162
The diﬀerence is even more pronounced in the colored T1-weighted spoiled
gradient echo image (Figure 4.3c) as well as T1 and T2 maps (Figure 4.3d-e).
Figure 4.3 The phantom (200 mm diameter, 24 mm diameter vials) with
TEEPO-Glc imaged with a 1.5 T clinical MRI scanner. (a) The
composition of the phantom. (b) T1-weighted spoiled gradient
echo (FLASH) image (ﬂip angle 90◦, echo time 4.76 ms, repeti-
tion time 400 ms) in grey scale and (c) in color. (d) The inversion
recovery T1 and (e) multi-spin-echo T2 maps of the phantom.
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For TEEPO-Met, a small phantom comprising nitroxide in 10 % DMSO in
blood plasma at concentrations of 0, 0.5, 1, 2, 5, 10 and 15 mM was constructed
(Figure 4.4a). The small phantom imaged with a human-sized scanner caused
some restrictions to the image quality which can be seen as a truncation arte-
fact causing dark pixels in the centre of each sample tube in Figure 4.4b-c. In
more detail, the artefact was caused by the low imaging resolution (0.8 mm /
pixel) in contrast to the sample tube size (4 mm). Nevertheless, the results
displayed a clear contrast between diﬀerent concentrations. In T1-weighted
spoiled gradient FLASH image with a 90◦ pulse, a clear contrast between sam-
ples of undoped and nitroxide-doped samples can be seen (Figure 4.4b-c). This
is also visible in T1 and T2 maps (Figure 4.4d-e).
Figure 4.4 The phantom (4 mm inner diameter tubes in a 17 mm diameter
spacer) with TEEPO-Met at concentrations of 0, 0.5, 1, 2, 5,
10 and 15 mM, imaged with a 1.5 T clinical MRI scanner. (a)
T1-weighted FLASH image (ﬂip angle 90◦, echo time 4.76 ms,
repetition time 400 ms) in grey scale and (b) in color. (c) The
inversion recovery T1 and (d) multi-spin-echo T2 maps of the
phantom.
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The relaxation times calculated from T1 and T2 maps showed similar results
with the preliminary pre-clinical 11.7 T ﬁeld strength studies (Figure 4.5)
Relaxivities r1 and r2 in 1.5 T for TEEPO-Glc were 0.23 mM-1 s-1 and 0.38
mM -1 s-1, respectively and for TEEPO-Met 0.31 mM-1 s-1 and 0.77 mM-1
s-1 (a rough estimate as the data is non-linear). Again, the DMSO used to
improve the solubility of TEEPO-Met in blood plasma may cause a more
eﬀective relaxation enhancement for TEEPO-Met. These relaxivity values are
in accordance with the values calculated for other monoradicals.115,163
Figure 4.5 The blood plasma water relaxation times and rates in the pres-
ence of TEEPO-Glc and TEEPO-Met in 1.5 T magnetic ﬁeld
collected from the phantom study. (a) T1 and (b) T2 relaxation
times as a function of TEEPO-Glc (black circle) and TEEPO-
Met (red triangle) concentrations. (c) R1 and (d) R2 (Rx =
1/Tx) relaxation rates as a function of TEEPO-Glc (black cir-
cle) and TEEPO-Met (red triangle) concentrations.
Although the values are signiﬁcantly lower than that of for example Gd-
(DTPA) (r1 4.1 mM-1 s-1 at 37 ◦C in 1.5 T),29 the possible targeting eﬀect
could compensate this ﬂaw by ensuring a suﬃcient concentration in the target
tissue without extreme contrast agent dosing. Approximate ratio values r2/r1
for TEEPO-Glc and TEEPO-Met, 1.7 and 2.5, respectively, suggest that the
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nitroxides could act mainly as T1 contrast agents. T1 contrast agents usually
have r2/r1 ratio of 1-2, whereas the ratio for T2 contrast agents is often 10 or
higher.19,44
4.1.5 In vitro cytotoxicity (I, III)
One of the advantages of using nitroxides as potential contrast agents is their
low toxicity.93,120 The in vitro cytotoxicity of TEEPO-Glc was studied with
cell viability and LDH release studies using two diﬀerent cell lines, HeLa cells
and HUVECs (human umbilical vein endothelial cells). To study the cell vi-
ability, the cells were treated with diﬀerent amounts of TEEPO-Glc (0.2, 1
and 10 mM) and incubated for 1, 6 and 24 hours. The cell viability was de-
termined using CellTiter-Glo R© assay. The assay is based on quantitation of
ATP (adenosine triphosphate) the amount of which is directly proportional to
the number of living cells. According to the results, at a high concentration
of TEEPO-Glc (10 mM) with long incubation time (24 h), the cell viability
of HeLa cells decreased signiﬁcantly (p<0.05) compared to unexposed controls
(Figure 4.6a). However, toxicity was not observed at shorter incubation times
(1 h and 6 h) or with smaller concentrations (0.2 mM and 1 mM) at any of
the time points (1, 6 or 24 h). For HUVECs, TEEPO-Glc signiﬁcantly re-
duced the cellular viability of cells exposed to a high concentration (10 mM)
of TEEPO-Glc for 1h (p<0.05), 6 h (p<0.05) or 24 h (p<0.05) (Figure 4.6b).
Nevertheless, low concentrations of TEEPO-Glc (0.2 mM or 1 mM) did not
aﬀect the cell viability.
The eﬀect of TEEPO-Glc was also investigated by the LDH release assay, a
colorimetric assay for the measurement of cytoplasmic LDH (lactate dehydro-
genase) enzyme activity. LDH is rapidly released from the cytosol in culture
medium upon damage of plasma membrane of the cells. The results from LDH
assay showed that none of TEEPO-Glc treatments (0.2, 1 and 10 mM) caused
a signiﬁcant membrane the damage up to 24 h for the cultured HeLa cells
(Figure 4.6c). With HUVECs, the highest concentration (10 mM) of TEEPO-
Glc induced a signiﬁcant LDH release (p<0.05) and loss of plasma membrane
integrity for all the tested time points (1, 6 and 24 h) when compared to un-
treated control cells (Figure 4.6d). Lower concentrations of TEEPO-Glc did
not show any membrane damaging eﬀects at any of the time points tested. All
in all, the TEEPO-Glc contrast agent showed toxicity only at a high 10 mM
concentration and can be considered scarcely toxic in concentrations relevant
for practical use.
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Figure 4.6 In vitro cytotoxicity of TEEPO-Glc. Cell viability study with
(a) HeLa cells and (b) HUVECs determined by CellTiter-Glo R©
assay kit. The results (mean ± SD, n=4) were compared to
untreated control cells with viability set at 100%. LDH release
study with (c) HeLa cells and (d) HUVECs. Control cells were
lysed with LDH assay lysis solution and set at 100% (Lysis).
The level of signiﬁcance was set at a probability of p<0.05 (*)
when compared with untreated control cells (Kruskal-Wallis with
Dunnett´s test).
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4.1.6 In vivo animal MRI studies (III)
The relaxation enhancing properties of TEEPO-Glc were also assessed with an
in vivo MRI study using Wistar rats. Unfortunately, solubility issues impeded
the in vivo studies of TEEPO-Met. Neither saline doped with 10 % DMSO
nor TWEEN20/80 produced a homogenous solution at the high concentration
(150 - 200 mM) required for the study.
In the study, T1 maps were collected before, during and after TEEPO-Glc
injection with inversion recovery FLASH imaging sequence in 9.4 T magnetic
ﬁeld. Figure 4.7 shows results of a representative animal, that was given in-
jections of TEEPO-Glc and Gd(DTPA) with a 60-minute time diﬀerence. By
that time the ﬁrst contrast agent had exited the tissue under study which
was observed by the recovery of the relaxation time. Gd(DTPA) was used
as a reference to compare the results of TEEPO-Glc to a common GBCA.
Figure 4.7a displays two sets of T1 images taken at approximately ten-minute
intervals after TEEPO-Glc (top row) and Gd(DTPA) (bottom row) injections.
The relaxation times were compared between two regions of interest (ROI):
tumor (red area) and normal, healthy brain (blue area). Figure 4.7b presents
the T1 relaxation times in tumor and normal, healthy brain areas with respect
to the time after the contrast agent injection. The values are voxel averages
from within each region of interest (ROI) and the error bands represent their
standard deviations (SD). The pre-injection relaxation time is longer in tumor
that in normal brain due to the diﬀerences in the tissue type.
The results show a clear drop in the T1 relaxation time in tumor after
the TEEPO-Glc injection. The eﬀect is strongest between 10 and 15 minutes
resulting in a decrease of approximately 20 % in T1. After 50 minutes, the T1
relaxation time returns to the level of pre-injection T1. In the healthy brain,
no decrease in the T1 relaxation times is detected. Compared to Gd(DTPA),
TEEPO-Glc shows similar behavior in relation to retention and accumulation
of the contrast agent. However, the relaxation eﬀect is much higher with
Gd(DTPA), supposedly due to the diﬀerence in the number of free electrons,
Gd(DTPA) having seven unpaired electrons in contrast to TEEPO-Glc having
one.
By contrast, the T2 values in tumor were not aﬀected by TEEPO-Glc even
though they showed a good contrast in the previous phantom study. Similar
to GBCAs, nitroxides seem to shorten both T1 and T2 times but the relative
eﬀect in tissue is much smaller for T2 than for T1 making them primarily T1
contrast agents.
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Figure 4.7 (a) T1 images of rat brain taken approximately every 10 minutes
after the TEEPO-Glc (top row) and Gd(DTPA) (bottom row)
injections. The red and blue contours enclose the tumor and
normal brain regions of interest (ROI), respectively. (b) The
T1 relaxation times within tumor and healthy brain ROI as a
function of time from contrast agent injection with error bands
(±SD).
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Also, the apparent concentrations of TEEPO-Glc in tumor were studied.
Table 4.1 presents the doses of TEEPO-Glc (animals 1–7) and Gd(DTPA)
(animals 3 and 8–10) injected to each animal. The maximal contrast agent
concentrations in tumor were calculated from the maximal R1 rates and the
r1 values. The r1 for TEEPO-Glc was determined to be 0.13 mM-1 s-1 at 9.4
T, which is in accordance with the values obtained in the earlier in vitro NMR
and phantom MRI studies, 0.12 mM-1 s-1 at 11.7 T and 0.23 mM-1 s-1 at 1.5
T ﬁeld. The concentrations were normalized with the injected TEEPO-Glc
dose to give the %ID/g (percent of injected dose per gram of tissue) values
(Table 4.1). According to the %ID/g values 0.19 ± 0.09 and 0.25 ± 0.09 for
TEEPO-Glc and Gd(DTPA), respectively, the uptakes of the contrast agents
are similar.
Table 4.1 Apparent contrast agent concentrations in tumor in each animal.
The animal in bold (3) received both contrast agents.
Animal
Injected
dose
(μmol/g)
Injected
dose
(μmol)
Apparent tumor
concentration
(mM ∼ μmol/g)
%ID/g
TEEPO-Glc 1 2.2 693 0.67 0.10
2 1.6 615 0.85 0.14
3 1.2 385 0.83 0.22
4 1.2 285 0.59 0.21
5 1.0 206 0.65 0.32
6 1.0 210 0.48 0.23
7 0.5 105 0.09 0.09
Average 0.19±0.08
Gd(DTPA) 3 0.1 34 0.12 0.37
8 0.1 37 0.05 0.15
9 0.1 37 0.09 0.24
10 0.1 33 0.09 0.27
Average 0.25±0.09
The concentrations are presented with respect to the time from the injection
in Figure 4.8. The values presented in the plot are averages of the animals
presented in Table 4.1. According to Student’s t-test, TEEPO-Glc exits the
tumor at a faster rate than Gd(DTPA) (p<0.01). The mean lifetimes were
23 ± 8 min and 49 ± 10 min for TEEPO-Glc and Gd(DTPA), respectively.
The rapid clearance and the similar uptake of the contrast agents may suggest
low targeting eﬀect of TEEPO-Glc. The targeting eﬀect could be further
studied using the radical moiety, 4-hydroxy-TEEPO, as a reference contrast
agent. However, due to its high lipophilicity, it was insoluble in pure saline
or saline doped with 10 % DMSO or TWEEN20/80 at desired concentrations.
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Additionally, the less lipophilic equivalent of 4-hydroxy-TEEPO, 4-hydroxy-
TEMPO, showed rapid bio-reduction losing its paramagnetism and ruling it
out as a reference.
Figure 4.8 The apparent concentration of TEEPO-Glc and Gd(DTPA) in
tumor as a function of time from TEEPO-Glc injection with
error bands (±SD).
4.2 Organic marker for MRS and MRSI
Magnetic resonance spectroscopy (MRS) and imaging (MRSI) are used to
study the metabolism in vivo. To our knowledge, there are no MRS / MRSI
markers targeted for speciﬁc tissue metabolism currently available. Usually,
the information on aberrations in metabolism are diagnosed by observing the
metabolite signal intensities and by comparing them with the intensities in
healthy tissue or their relation to other metabolite intensities. In healthy brain,
the metabolite signals are usually located at 0.5-5.0 ppm in 1H MRS spectrum.
In this study, a marker consisting of glucose labeled with trimethylsilyl (TMS)
group was developed. Trimethylsilyl group is usually detected close to 0 ppm
in 1H spectrum, an area where no natural metabolites appear. Glucose could
potentially act as a targeting moiety towards the increased metabolism in tu-
mor tissue. Consequently, a signal at 0 ppm in 1H spectrum would suggest
an increased uptake of glucose in the area under investigation, and a potential
tumor ﬁnding and characterization.
4.2. ORGANIC MARKER FOR MRS AND MRSI 41
4.2.1 TMSEt-Glc
In the study, glucose unit (Glc) was used as a potential targeting unit due to its
superior water solubility and its fuction as brain energy source. It was labeled
with TMS group via an ethyl bridge in order to bring the 1H NMR signal of the
TMS groups closer to 0 ppm. For the synthesis, peracetylated glucose 54 was
treated with hydrogen bromide solution (33% in AcOH) (Scheme 4.4). The
resulting α-acetobromoglucose 55 was used as a donor in the reaction with 2-
TMS-ethanol as acceptor, with AgOTf (silver triﬂuoromethanesulfonate) and
2,4,6-trimethylpyridine activation.164 Deacetylation of 56 was performed by
stirring the compound with 25 % ammonia solution in methanol at room tem-
perature yielding TMSEt-Glc (2-(trimethylsilyl)ethyl β-D-glucopyranoside) 57
as the ﬁnal product.
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Scheme 4.4 Synthesis of TMSEt-Glc 57 with reagents and conditions.
4.2.2 Stability towards dissociation
The possible undesired transformation of TMSEt-Glc is the dissociation to glu-
cose and TMSEtOH. The most propable mechanism for this process in vivo is
hydrolysis of the glycosidic bond (Scheme 4.5) catalysed by glycosidase enzyme.
The anomeric conformation of the resulting glucose is enzyme dependent.165
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Scheme 4.5 Dissociation of TMSEt-Glc 57 to glucose 58 and TMSEtOH
59 by glycosidic bond hydrolysis.
The stability of the glycosidic bond in TMSEt-Glc was evaluated by a
simple in vitro stability test. The compound was incubated at a 10 mM con-
centration in human blood plasma at 37 ◦C for 1, 2, 3 and 24 hours and
the potential dissociation reaction was monitored with NMR spectroscopy by
HMBC145 (Heteronuclear Multiple Bond Correlation) experiment. In the spec-
tra, a correlation between the anomeric proton H -1’ (4.41 ppm) of the glucose
moiety and –CH2-carbon (71.10 ppm) of the ethyl-TMS moiety can be clearly
detected even after 24 hours (Figure 4.9). This result suggests that the com-
pound is stable and does not go through dissociation reaction in biological
matrix and conditions similar to living organisms.
Figure 4.9 The HMBC spectrum of TMSEt-Glc in human blood plasma
with 10 % of D2O. A clear correlation between H -1’ and –CH2
can be seen.
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4.2.3 Spectroscopic phantom studies
To study the TMSEt-Glc as a potential marker for MRS and MRSI, a phantom
was constructed and imaged in 9.4 T magnetic ﬁeld. The phantom consisted
of varying concentration of TMSEt-Glc (0.0625 mM, 0.125 mM, 0.25 mM, 0.5
mM, 1 mM, 2 mM) in a buﬀered solution containing various common metabo-
lites to imitate a biological matrix. The metabolites used in the study were
lactate (Lac), N -acetyl aspartate (NAA), glutamine (Gln), creatine, choline
(Cho) and myo-inositol (mI). From a single voxel MRS spectrum in Figure 4.10
it can be seen that the TMS-signal of TMSEt-Glc becomes visible at a concen-
tration of 0.125 mM with in vitro conditions. After the concentration reaches
0.5 mM, the signal is clearly visible compared to some of the metabolites with
higher concentration such as lactate (2 mM) glutamine (9 mM) or creatine (6
mM). That is due to the large number of protons in the TMS group consisting
of three –CH3 groups appearing as a singlet at 0 ppm in the spectrum.
Figure 4.10 MRS spectra of TMSEt-Glc at concentrations of 0.0625 mM,
0.125 mM, 0.25 mM, 0.5 mM, 1 mM and 2 mM in a buﬀered
solution doped with most common metabolites. The TMSEt-
Glc concentration is increasing from top to bottom.
In addition to single voxel MRS, a chemical shift imaging (CSI) was per-
formed to obtain MRSI color maps of the phantom metabolites. The color
maps obtained from integrations of TMSEt-Glc and NAA signals are presented
in Figure 4.11. As expected, the distribution of TMSEt-Glc varies in propor-
tion to the concentration (Figure 4.11b). Also, an uniform distribution of NAA
can be distinguished as all the sample tubes contain the same amount of NAA
(Figure 4.11c). Altogether, an increase similar to results with 1H MRS in signal
intensity can be seen as the concentration of TMSEt-Glc becomes larger.
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Figure 4.11 Chemical shift imaging of the phantom (4 mm inner diameter
tubes in a 17 mm diameter spacer) in 9.4 T magnetic ﬁeld.
Color maps obtained from integration of TMSEt-Glc (center)
and NAA signals (right) overlaid on gradient echo MR image
(left). The integration regions were -0.2–0.1 and 1.9–2.2 for
TMSEt-Glc and NAA, respectively.
Disappointingly, the in vivo animal 1H MRS studies with Wistar rats
showed no traces of TMSEt-Glc in the tumor area or in the brain area. The
reasons for this could not be deﬁned. According to the stability test, it is
unlikely that the compound dissociates in vivo. It is possible that the concen-
tration required for a detectable signal could not be reached in the area under
investigation.
5 Conclusions
In this study, two stable, metal-free nitroxides with contrast enhancing abil-
ities were developed. The compounds comprised a paramagnetic nitroxide
moiety TEEPO and a glucose (Glc) or methionine (Met) moiety designed to
act as a potential targeting unit. The stability of the resulting TEEPO-Glc
and TEEPO-Met towards reduction by a natural reductant, ascorbic acid, was
evaluated by using NMR and EPR-spectroscopy, respectively. Both of the
compounds displayed superior stability, which is directly proportional to the
size of the steric hindrance provided by the side groups adjacent to the radical
center. Their eﬀect on the relaxation times of the surrounding water protons
were assessed in both pre-clinical (11.7 T) and clinical (1.5 T) ﬁelds with in
vitro NMR and phantom MRI studies. Both TEEPO-Glc and TEEPO-Met
showed relaxation enhancing properties having r1 values of 0.12 mM-1 s-1 and
0.17 mM-1 s-1 in pre-clinical ﬁled, and 0.23 mM-1 s-1 and 0.31 mM-1 s-1 in clin-
ical ﬁeld, respectively. The applicability of TEEPO-Glc as an MRI contrast
agent was also assessed with a in vivo animal MRI study in 9.4 T ﬁeld. The
study gave similar results with the in vitro studies, i.e. TEEPO-Glc was able
to shorten T1 relaxation time also in vivo. Although the results of the phan-
tom study indicated that TEEPO-Glc also reduces the T2 relaxation time of
nearby water protons, the in vivo animal study showed no shortening in the T2
relaxation time. Consequently, a water soluble metal-free contrast agent with
similar behaviour to Gd(DTPA), concerning accumulation and relaxation en-
hancement in the tumor area, was conﬁrmed. The relaxation enhancement
was obviously smaller for TEEPO-Glc, due to the higher amount of unpaired
electrons in Gd(DTPA). Unfortunately, the targeting eﬀects could not be as-
sessed with this study. Also, improving the water solubility of TEEPO-Met
at high concentrations requires further attention. According to these results,
TEEPO-based compounds conjugated with targeting units show potential as
T1 contrast agents for MRI.
Furthermore, an organic marker for magnetic resonance spectroscopy and spec-
troscopic imaging was designed. The marker consisted of a tumor targeting
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unit, glucose, labelled with a TMS-group. According to the results of a spec-
troscopic phantom study, the compound gave a considerably large signal with
a relatively low concentration. Also, the signal appeared at 0 ppm, a spectral
region where no natural metabolites appear. Disappointingly, the in vivo ani-
mal studies showed no traces of the marker in any area of the research subject.
According to an in vitro stability study, no dissociation of TMS from the glu-
cose moiety should occur in biological matrix indicating that additional work
is required to work out the root cause for the invisibility of the signal.
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